We are live on ! Find out more
TTNP

Titan Pharmaceuticals
TTNP

Delisted

TTNP was delisted on the 1st of October, 2025.

Back to rankings

19 hedge funds and large institutions have $374K invested in Titan Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 1

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

6% more funds holding

Funds holding: 18 → 19 (+1)

0.29% less ownership

Funds ownership: 0.54% → 0.25% (-0.29%)

70% less capital invested

Capital invested by funds: $1.24M → $374K (-$869K)

Holders
19
Holders Change
+1
Holders Change %
+5.56%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
7
Reduced
1
Closed
3
Calls
$6K
Puts
–
Net Calls
+$6K
Net Calls Change
-$7K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$127K
2
VF
Virtu Financial
New York
+$38.9K
3
Millennium Management
Millennium Management
New York
+$33K
4
HF
HRT Financial
New York
+$32.5K
5
UBS Group
UBS Group
Switzerland
+$12.4K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$826K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$82K
3
Barclays
Barclays
United Kingdom
-$48K
4
TRCT
Tower Research Capital (TRC)
New York
-$10K

TTNP Hedge Fund Activity: Q2 2022 in Review

19 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q2 2022, worth a combined $374K — down 70% from $1.24M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new TTNP positions and 3 closed out — a net gain of 1 holder — while 7 added to existing stakes and 1 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $127K. The largest seller was Armistice Capital, exiting entirely with an estimated $826K sold.

  • 19 institutional investors held Titan Pharmaceuticals (TTNP) as of Q2 2022, up from 18 in Q1 2022.
  • Funds reported $374K of Titan Pharmaceuticals stock for Q2 2022, down 70% quarter-over-quarter.
  • 4 funds opened new Titan Pharmaceuticals positions in Q2 2022 and 3 closed out, a net change of +1 holder.
  • The largest Titan Pharmaceuticals buyer in Q2 2022 was Renaissance Technologies, an estimated $127K added.
  • The largest Titan Pharmaceuticals seller in Q2 2022 was Armistice Capital, an estimated $826K sold.

Based on aggregated 13F filings for Q2 2022.